GSK's ViiV gives early look at HIV broadly neutralizing antibody's power, eyes...

[cafead]

via Existing HIV antiretroviral therapies are mostly small-molecule drugs that require daily medication. Broadly neutralizing antibodies (bNAbs) hold promise as potential longer-term options, and GSK’s ViiV Healthcare has provided encouraging early proof-of-concept data for such a candidate.

article source